Search Results
Multiple Myeloma Support from the Microenvironment: Bone Marrow Adipocytes and the Fatty Acid Binding Proteins
Our project’s goal is to change how multiple myeloma is understood and treated by interrogating a novel part of the cellular “soil” (the bone marrow adipocyte), in which myeloma cells, or “seeds”, land and grow. We will discover new forms of cancer drug resistance that are driven by adipocyte-derived factors and the fatty acid binding proteins. This work will expose new ways to overcome drug resistance to improve survival and quality of life for myeloma and other hematological cancer patients.
A phase 1 study of CB-011, a CRISPR-edited allogeneic CAR-T targeting BCMA, in patients with multiple myeloma
In February 2021, LLS made an equity investment in Caribou Biosciences to support "A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma." Caribou is a leading clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.
Honoring Blood Cancer Survivors
Throughout June, in commemoration of #NationalCancerSurvivorMonth, we at LLS have been highlighting the resilience and achievements of blood cancer survivors. I’ve treated so many incredible young survivors in my years as a pediatric hematologist oncologist, and all of them hold a special place in my heart.
Dissect the function of histone demethylase KDM5 on overcoming drug resistance toward immunotherapy in multiple myeloma
We identified that KDM5 can regulate important transcription factors in multiple myeloma (MM) and regulate the bone marrow (BM) microenvironment in providing protection toward MM, which also reduces anti-MM immunity. Thus, our study will utilize our novel potent and selective KDM5 inhibitor to fully dissect the interactions between MM cells, the BM microenvironment and the immune system in cellular and animal models to establish important mechanistic insights into MM.Early Detection and Intervention in Smoldering Multiple Myeloma: population-based screening and treatment; Edit-SMM
We build on the success from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study, where over 80,000 consented to a nationwide screening for MM precursors. A unique cohort of patients with SMM diagnosed in iStopMM will be followed by clinical evaluation, linking to central health data registries, using novel biomarkers, and in-depth genetics. With precision early treatment we aim to induce a paradigm shift leading to improved quality of life and potentially a cure for MM.Improving outcomes of multiple myeloma using TGF-beta resistant BCMA-targeted CAR T cells
Immunotherapy using chimeric antigen receptor (CAR) T cells, or CARTs for short, holds great promise for improving outcomes and survival of patients with relapsed and/or refractory multiple myeloma (RRMM). Next-generation “armored” CARTs that can overcome transforming growth factor beta (TGF-beta) dependent immune suppression in the tumor microenvironment may provide deeper and more durable disease control than the TGF-beta sensitive CART products currently in clinical use.Myeloma Overview
Myeloma Link Connecting African American Communities to Information, Expert Care, and SupportAs black Americans are at twice the risk for myeloma as whites, The Leukemia & Lymphoma Society has created Myeloma Link to increase access to education and treatment for myeloma in African American communities.
Ixazomib
Ixazomib is FDA approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Development of a novel BCL2L1 armored CAR T-cell and a tumor-immune interactome in multiple myeloma
Novel immune approaches have revolutionized the treatment paradigms in multiple myeloma (MM) with deep responses seen in heavily pretreated patients. However responses are largely not durable with significant gaps remaining in our understanding of the mechanisms mediating the immune escape to to CAR T cells and T cell engagers.Talquetamab-tgvs
Talquetamab-tgvs is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Elranatamab-bcmm
Elranatamab-bcmm is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Melphalan hydrochloride
U.S. Food and Drug Administration (FDA) has granted approval of EVOMELA for use in two indications:
- Use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma (MM)
- For the palliative treatment of patients with MM for whom oral therapy is not appropriate.
This is the first product to be FDA-approved for the high-dose conditioning indication in MM.
Ciltacabtagene autoleucel
Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Pomalidomide
Pomalidomide is FDA approved to treat people with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Teclistamab-cqyv
Tecvayli™ (teclistamab‑cqyv) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Roughly half of all ALL cases occur in adults, and unlike pediatric ALL, adults have historically had a poor prognosis. This approval, which follows an FDA Breakthrough Therapy Designation and priority review, is a meaningful advance for these patients.